Ultragenyx Pharma RARE

HealthcareMarket cap $5B1 connection

Ultragenyx develops therapies for ultra-rare genetic diseases - conditions so uncommon that traditional pharma won't invest in them. Its approved drugs (Crysvita for XLH, Mepsevii for MPS VII) serve patients with nowhere else to turn. Rare disease drugs qualify for expedited FDA review, 7-year market exclusivity, and tax credits - and command extraordinary prices because patients have no alternatives.

Explore Ultragenyx Pharma on the interactive map Relationship timeline Find a path to another company

Competitors 1

Companies it competes with

BioMarin PharmaHealthcare · $15BRare disease therapies

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Ultragenyx Pharma's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=RARE" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Ultragenyx Pharma on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.